Dusica Cvetkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dusica Cvetkovic has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Charlie M. Ma
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA, philadelphia, Pennsylvania, 19111, UNITED STATES
23 shared publications - Aditya Kulkarni
Lantern Pharma Inc., Dallas, Texas
20 shared publications - Diana Restifo
Fox Chase Cancer Center, Philadelphia, PA
20 shared publications - Igor Astsaturov
Fox Chase Cancer Center, Philadelphia, USA
20 shared publications - Joseph R. McDermott
Lantern Pharma Inc., Dallas, Texas
20 shared publications - Kishor Bhatia
Lantern Pharma Inc., Dallas, Texas
20 shared publications
Latest Publications
- 18 January 2026
- Published by Wiley in Medical Physics
- Vol. 53 (1) , e70290
Efficacy and Energy Dependence of Radiodynamic Therapy: 6–45MV photon beams with 5‐aminolevulinic acid
Background: There is a growing interest in radiodynamic therapy (RDT), which combines the principles of radiotherapy and photodynamic therapy (PDT) to enhance tumoricidal capabilities while limiting toxicities to healthy tissues. RDT utilizes the cellular damage caused by high‐energy radiation and the photosensitizer activation within cancer cells. Purpose: 5‐aminolevulinic acid (5‐ALA)‐mediated RDT exploits the x‐ray irradiation and activation of protoporphyrin IX (PpIX), which is metabolized from 5‐ALA. Cherenkov light induced by megavoltage photon beams effectively activates PpIX due to the Soret band (the intense absorption peak in the blue region of the visible spectrum). The emission of Cherenkov light increases with photon energy in water and ex vivo tissues. Based on this, our study aimed to investigate the tumor response and photon efficacy of RDT combined with 5‐ALA administration and megavoltage photon radiation treatment in an in vivo mouse model. Methods: A preclinical in vivo murine small‐cell lung cancer model in immunocompetent C57BL/6 mice was examined. The tumors ( n = 400) were randomized into eight groups: control (untreated), 5‐ALA only, 6, 15, and 45 MV radiation treatment (RT) only, and 6, 15, and 45 MV RDT (5‐ALA+RT) to observe individual and synergistic effects of 5‐ALA and RT. A radiation dose of 4 Gy in a single fraction was delivered to the tumors using half‐body irradiation using 6, 15, and 45 MV photons. 5‐ALA was injected at 100 mg/kg intravenously 4 h before irradiation. Tumor volumes were measured using a 1.5 T MR scanner on the day of treatment (prior to the treatment, initial volume at the start of the study), and 3‐, 7‐, and 14‐day posttreatment. Normal tissue toxicity was assessed on the hematoxylin‐eosin (H&E)‐stained microscope slides using the standard histopathologic score. Results: The most significant decrease in tumor growth was achieved 14‐day posttreatment with 45 MV RDT by 52.7 ± 3.7 %, 52.4 ± 3.8 %, and 47.6 ± 4.2 % compared to the control, 5‐ALA only, and 45 MV RT only, respectively ( P < 0.001). Likewise, 45 MV RDT resulted in an additional 36.6 ± 4.2 % and 17.0 ± 8.1 % decrease in tumor growth compared to 6 and 15 MV RDT 14‐day posttreatment, respectively ( P < 0.001), whereas RT only did not show significant differences across all photon energies. Based on these results, an additional 47.3 ± 8.2 % decrease in tumor growth was estimated as a synergistic effect in the RDT groups compared to 5‐ALA and RT only groups. The results of our histopathologic analysis showed similarities in normal tissue toxicities between RT and RDT. Conclusion: A combination of 5‐ALA administration and megavoltage photon irradiation demonstrated an enhancement of the therapeutic efficacy, potentially leading to better patient outcomes. The treatment outcome was improved with higher energy because of photon energy dependence, whereas the conventional radiation treatment was not improved. Overall, the benefit of radiation treatment and PDT was synergistic and achieved in one treatment session.
- 18 January 2026
- Published by Wiley in Medical Physics
- Vol. 53 (1) , e70290
Efficacy and Energy Dependence of Radiodynamic Therapy: 6–45MV photon beams with 5‐aminolevulinic acid
Background: There is a growing interest in radiodynamic therapy (RDT), which combines the principles of radiotherapy and photodynamic therapy (PDT) to enhance tumoricidal capabilities while limiting toxicities to healthy tissues. RDT utilizes the cellular damage caused by high‐energy radiation and the photosensitizer activation within cancer cells. Purpose: 5‐aminolevulinic acid (5‐ALA)‐mediated RDT exploits the x‐ray irradiation and activation of protoporphyrin IX (PpIX), which is metabolized from 5‐ALA. Cherenkov light induced by megavoltage photon beams effectively activates PpIX due to the Soret band (the intense absorption peak in the blue region of the visible spectrum). The emission of Cherenkov light increases with photon energy in water and ex vivo tissues. Based on this, our study aimed to investigate the tumor response and photon efficacy of RDT combined with 5‐ALA administration and megavoltage photon radiation treatment in an in vivo mouse model. Methods: A preclinical in vivo murine small‐cell lung cancer model in immunocompetent C57BL/6 mice was examined. The tumors ( n = 400) were randomized into eight groups: control (untreated), 5‐ALA only, 6, 15, and 45 MV radiation treatment (RT) only, and 6, 15, and 45 MV RDT (5‐ALA+RT) to observe individual and synergistic effects of 5‐ALA and RT. A radiation dose of 4 Gy in a single fraction was delivered to the tumors using half‐body irradiation using 6, 15, and 45 MV photons. 5‐ALA was injected at 100 mg/kg intravenously 4 h before irradiation. Tumor volumes were measured using a 1.5 T MR scanner on the day of treatment (prior to the treatment, initial volume at the start of the study), and 3‐, 7‐, and 14‐day posttreatment. Normal tissue toxicity was assessed on the hematoxylin‐eosin (H&E)‐stained microscope slides using the standard histopathologic score. Results: The most significant decrease in tumor growth was achieved 14‐day posttreatment with 45 MV RDT by 52.7 ± 3.7 %, 52.4 ± 3.8 %, and 47.6 ± 4.2 % compared to the control, 5‐ALA only, and 45 MV RT only, respectively ( P < 0.001). Likewise, 45 MV RDT resulted in an additional 36.6 ± 4.2 % and 17.0 ± 8.1 % decrease in tumor growth compared to 6 and 15 MV RDT 14‐day posttreatment, respectively ( P < 0.001), whereas RT only did not show significant differences across all photon energies. Based on these results, an additional 47.3 ± 8.2 % decrease in tumor growth was estimated as a synergistic effect in the RDT groups compared to 5‐ALA and RT only groups. The results of our histopathologic analysis showed similarities in normal tissue toxicities between RT and RDT. Conclusion: A combination of 5‐ALA administration and megavoltage photon irradiation demonstrated an enhancement of the therapeutic efficacy, potentially leading to better patient outcomes. The treatment outcome was improved with higher energy because of photon energy dependence, whereas the conventional radiation treatment was not improved. Overall, the benefit of radiation treatment and PDT was synergistic and achieved in one treatment session.
- 11 December 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 12 (1) , 015018
An in vitro investigation of 5-aminolevulinic acid and acridine orange as sensitizers in radiodynamic therapy for prostate and breast cancer
Purpose. Radiodynamic Therapy (RDT) is an emerging technique that enhances the therapeutic effects of radiation by using photosensitizers to amplify tumor cell damage while minimizing harm to normal tissues. This in vitro investigation compares the biocompatibility and sensitizing efficacy of two candidate photosensitizers, 5-aminolevulinic acid (5-ALA) and acridine orange (AO), in human breast adenocarcinoma (MCF7) and prostate adenocarcinoma (PC3) cell lines. Materials and Methods. MCF7 and PC3 cell lines were cultured and exposed to a range of 5-ALA and AO concentrations to assess biocompatibility using PrestoBlue viability assays. Based on these results, optimal concentrations were selected for irradiation experiments. Cells were then seeded in T-25 flasks and incubated with 5-ALA or AO prior to receiving 2 Gy or 4 Gy of megavoltage photon radiation (18 MV or 45 MV). Clonogenic assays were performed to determine the surviving fractions of the cells. Results . 5-ALA exhibited a broader biocompatibility profile than AO, remaining non-cytotoxic up to 100 μg ml −1 . In contrast, AO showed cytotoxic effects above 1 μg ml −1 . At 18 MV, limited radiosensitization was observed, except at higher 5-ALA concentrations. However, at 45 MV, both sensitizers significantly reduced cell survival, particularly at 4 Gy. The most pronounced effect was observed with 100 μg ml −1 5-ALA, which consistently resulted in lower surviving fractions than AO across both cell lines. Each sensitizer demonstrated differing effectiveness depending on the cell line and photon energy used. Conclusions . Both 5-ALA and AO enhanced the cytotoxic effects of radiation, but 5-ALA demonstrated superior biocompatibility and more consistent radiosensitization across both cell lines. Notably, the effectiveness of both sensitizers increased with higher photon energy, reinforcing the importance of beam energy in RDT design. These results underscore the advantages of 5-ALA over AO and highlight the need to optimize both sensitizer selection and radiation energy in clinical applications.
- 11 December 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 12 (1) , 015018
An in vitro investigation of 5-aminolevulinic acid and acridine orange as sensitizers in radiodynamic therapy for prostate and breast cancer
Purpose. Radiodynamic Therapy (RDT) is an emerging technique that enhances the therapeutic effects of radiation by using photosensitizers to amplify tumor cell damage while minimizing harm to normal tissues. This in vitro investigation compares the biocompatibility and sensitizing efficacy of two candidate photosensitizers, 5-aminolevulinic acid (5-ALA) and acridine orange (AO), in human breast adenocarcinoma (MCF7) and prostate adenocarcinoma (PC3) cell lines. Materials and Methods. MCF7 and PC3 cell lines were cultured and exposed to a range of 5-ALA and AO concentrations to assess biocompatibility using PrestoBlue viability assays. Based on these results, optimal concentrations were selected for irradiation experiments. Cells were then seeded in T-25 flasks and incubated with 5-ALA or AO prior to receiving 2 Gy or 4 Gy of megavoltage photon radiation (18 MV or 45 MV). Clonogenic assays were performed to determine the surviving fractions of the cells. Results . 5-ALA exhibited a broader biocompatibility profile than AO, remaining non-cytotoxic up to 100 μg ml −1 . In contrast, AO showed cytotoxic effects above 1 μg ml −1 . At 18 MV, limited radiosensitization was observed, except at higher 5-ALA concentrations. However, at 45 MV, both sensitizers significantly reduced cell survival, particularly at 4 Gy. The most pronounced effect was observed with 100 μg ml −1 5-ALA, which consistently resulted in lower surviving fractions than AO across both cell lines. Each sensitizer demonstrated differing effectiveness depending on the cell line and photon energy used. Conclusions . Both 5-ALA and AO enhanced the cytotoxic effects of radiation, but 5-ALA demonstrated superior biocompatibility and more consistent radiosensitization across both cell lines. Notably, the effectiveness of both sensitizers increased with higher photon energy, reinforcing the importance of beam energy in RDT design. These results underscore the advantages of 5-ALA over AO and highlight the need to optimize both sensitizer selection and radiation energy in clinical applications.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figures and tables legends from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary figure legends and Tables
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures and tables legends from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary figure legends and Tables
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Supplementary Table 1 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
- 7 August 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (5)
Radiodynamic Therapy as a Potential Strategy for Metastatic Control in Small-cell Lung Cancer: A Preclinical Study
Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterized by early metastatic dissemination and poor survival. Radiodynamic therapy (RDT), which combines radiation with a photosensitizer to enhance tumor control, has shown an improved therapeutic effect over conventional radiotherapy (RT) in preclinical solid tumor models. Given the limited effectiveness of conventional RT in controlling metastatic disease, we investigated whether RDT could provide a therapeutic advantage in a premetastatic SCLC model. To guide treatment timing, histological analysis of lung tissue from untreated control mice was performed at defined intervals after tumor cell inoculation, revealing early establishment of micrometastases. Using this framework, we treated immunocompetent C57BL/6 mice inoculated with KP1 SCLC cells with a single fraction of low-dose (0.1 Gy) or high-dose (2 Gy) RDT and evaluated metastasis progression and survival. MRI assessment of tumor burden revealed that both low-dose and high-dose RDT delayed metastasis progression compared to RT and control groups, which exhibited significant tumor burden at earlier time points. Kaplan-Meier survival data analysis demonstrated a significant survival benefit in RDT treated mice compared to RT and control groups, with statistical analysis confirming a significant extension of lifespan in both RDT cohorts (p < 0.004). These findings show that RDT reduces the rate of metastatic progression and improves survival outcomes in a premetastatic SCLC model, supporting its potential as a systemic therapeutic strategy for metastases.
- 7 August 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (5)
Radiodynamic Therapy as a Potential Strategy for Metastatic Control in Small-cell Lung Cancer: A Preclinical Study
Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterized by early metastatic dissemination and poor survival. Radiodynamic therapy (RDT), which combines radiation with a photosensitizer to enhance tumor control, has shown an improved therapeutic effect over conventional radiotherapy (RT) in preclinical solid tumor models. Given the limited effectiveness of conventional RT in controlling metastatic disease, we investigated whether RDT could provide a therapeutic advantage in a premetastatic SCLC model. To guide treatment timing, histological analysis of lung tissue from untreated control mice was performed at defined intervals after tumor cell inoculation, revealing early establishment of micrometastases. Using this framework, we treated immunocompetent C57BL/6 mice inoculated with KP1 SCLC cells with a single fraction of low-dose (0.1 Gy) or high-dose (2 Gy) RDT and evaluated metastasis progression and survival. MRI assessment of tumor burden revealed that both low-dose and high-dose RDT delayed metastasis progression compared to RT and control groups, which exhibited significant tumor burden at earlier time points. Kaplan-Meier survival data analysis demonstrated a significant survival benefit in RDT treated mice compared to RT and control groups, with statistical analysis confirming a significant extension of lifespan in both RDT cohorts (p < 0.004). These findings show that RDT reduces the rate of metastatic progression and improves survival outcomes in a premetastatic SCLC model, supporting its potential as a systemic therapeutic strategy for metastases.
- Open Access
Investigation of Normal Tissue Toxicity in Pulsed Low Dose Rate Radiotherapy
Purpose: Pulsed low dose rate radiotherapy (PLDR) is a radiotherapy approach expected to reduce normal tissue toxicity while maintaining equivalent tumor control as conventional radiotherapy (CRT). This preliminary study evaluates the effectiveness of PLDR in reducing normal tissue toxicity in vivo. Materials and Methods: In the initial phase, C57BL/6 mice underwent histological examination following single-fraction, total-body irradiation. Observations were conducted at 3 and 5 days post-treatment. Mice were divided into control, PLDR, and CRT groups, receiving varying doses ranging from 4 to 12 Gy. Building upon the histological findings, the second phase centered on whole-abdominal irradiation (WAI) and determining the lethal dose for WAI using CRT. Subsequently, this dose was applied in PLDR settings to compare survival rates and changes in body weight. The experiment was replicated to collect histology samples at 1-, 3-, 5-, 7-, and 9-day endpoints, enabling the assessment and comparison of tissue toxicity. Finally, exploration into PLDR’s lethal WAI dose was conducted. Results: Histology results showed the abdominal region as the main site of difference between PLDR and CRT, with both methods causing a dose-dependent increase in atrophy and hyperplasia. However, CRT led to higher tissue toxicity compared to PLDR. In the survival study, the fatal dose for WAI treatment was 18 Gy, with mice in the CRT group experiencing substantial weight loss and dying within 9–12 days post-treatment. In contrast, mice in the PLDR group, despite an initial weight loss, recovered their weight and survived. Histology results also showed that the PLDR group had less tissue toxicity. Furthermore, the fatal dose of WAI for PLDR was revealed to be 29 Gy, which is over 60% higher than the dose required for CRT, indicating a substantial difference in tolerance and potential safety margin provided by PLDR treatment. Conclusions: PLDR demonstrated a reduced normal toxicity compared to CRT, potentially beneficial in re-treatment scenarios or for tumors where CRT-induced toxicity limits tumor control, such as in liver cases.
Open AccessInvestigation of Normal Tissue Toxicity in Pulsed Low Dose Rate Radiotherapy
Purpose: Pulsed low dose rate radiotherapy (PLDR) is a radiotherapy approach expected to reduce normal tissue toxicity while maintaining equivalent tumor control as conventional radiotherapy (CRT). This preliminary study evaluates the effectiveness of PLDR in reducing normal tissue toxicity in vivo. Materials and Methods: In the initial phase, C57BL/6 mice underwent histological examination following single-fraction, total-body irradiation. Observations were conducted at 3 and 5 days post-treatment. Mice were divided into control, PLDR, and CRT groups, receiving varying doses ranging from 4 to 12 Gy. Building upon the histological findings, the second phase centered on whole-abdominal irradiation (WAI) and determining the lethal dose for WAI using CRT. Subsequently, this dose was applied in PLDR settings to compare survival rates and changes in body weight. The experiment was replicated to collect histology samples at 1-, 3-, 5-, 7-, and 9-day endpoints, enabling the assessment and comparison of tissue toxicity. Finally, exploration into PLDR’s lethal WAI dose was conducted. Results: Histology results showed the abdominal region as the main site of difference between PLDR and CRT, with both methods causing a dose-dependent increase in atrophy and hyperplasia. However, CRT led to higher tissue toxicity compared to PLDR. In the survival study, the fatal dose for WAI treatment was 18 Gy, with mice in the CRT group experiencing substantial weight loss and dying within 9–12 days post-treatment. In contrast, mice in the PLDR group, despite an initial weight loss, recovered their weight and survived. Histology results also showed that the PLDR group had less tissue toxicity. Furthermore, the fatal dose of WAI for PLDR was revealed to be 29 Gy, which is over 60% higher than the dose required for CRT, indicating a substantial difference in tolerance and potential safety margin provided by PLDR treatment. Conclusions: PLDR demonstrated a reduced normal toxicity compared to CRT, potentially beneficial in re-treatment scenarios or for tumors where CRT-induced toxicity limits tumor control, such as in liver cases.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies
Supplementary Table 2 from Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies